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1. Introduction
  Tuberculosis (TB) is a deadly infectious disease caused by 
various strains of mycobacterium, usually Mycobacterium 
tuberculosis (M. tuberculosis). Tuberculosis has been 
considered to be a disease of poverty for many years with 
quite rare occurrence in the developed countries. With 
people in developed countries having their immune systems 
compromised by immunosuppressive drugs, substance 
abuse or AIDS, the situation has unfortunately been 
aggravated by contracting tuberculosis[1]. The sudden rise 
of tuberculosis was declared by World Health Organization 
(WHO) as a global emergency with 9 million new TB cases 
and two million deaths reported each year[2,3]; and about 
one-third of the world’s population is currently reported 
to be infected with M. tuberculosis. Despite the efforts of 
academic institutions and the pharmaceutical companies 
engaged in the design, synthesis, and development of new 
antitubercular regimens, the current TB therapeutic arsenal 
is poor. It has been claimed that several plant natural 
products inhibit several species of mycobacteria[4, 5].
  The tropical Philippine medicinal plant Uvaria rufa (U. 
rufa) Blume (“susung kalabaw” in Filipino) is a short 
climbing shrub that grows in low- and medium-altitude 
forests located in Northern Luzon to Palawan and Mindanao. 
Traditionally, the alcoholic root extract is introduced to 
laboring women to induce urine contractions (ecbolic)[6]. 
A triterpene, flavonoid and their glycosides and essential 
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oils were previously described in U. rufa. In addition to 
these constituents, a number of highly oxidized cyclohexene 
derivatives have been identified in samples collected in 
Asia[7-9]. Isoquercitrin and isoquercitrin-6-acetate, two 
flavonoids from Thai U. rufa, were found comparable with 
quercetin in inhibiting the formation of advanced glycation 
end-products (AGEs)[10]. As part of an on-going search 
for anti-TB phytochemicals from Philippine medicinal
plants[11-16], we report in this paper the in vitro inhibitory 
activity of the chloroform extract and its lead acetate – 
treated extract, petroleum ether and chloroform sub-
extracts, their fractions and metabolites 1-7 (Figure 1) 
from the leaves of U. rufa Blume (Annonaceae) against
M. tuberculosis H37Rv.
 
2. Materials and methods
2.1. Plant collection
  U. rufa was collected from Santa, Ilocos Sur, Philippines in 
April 2004. The voucher specimen (USTH4897) was deposited 
in the Herbarium of Plant Sciences Laboratory, Research 
Center for Natural and Applied Sciences. Taxonomic 
identification was done by Asst. Prof. Rosie S. Madulid.
2.2. Plant extraction and fractionation 
  Ground, air-dried leaf samples of U. rufa (3.34 kg) were 
extracted with chloroform (CHCl3) to give a green (UrC, 482 g)
syrupy extract. A portion of UrC (150 g) was subjected to 
solvent partitioning in water with 50% hexanes in MeOH, 
and CHCl3 to give two sub-extracts namely, UrCP (15 
g) and UrCC (106 g). Bioactive UrCC was subjected to 
gradient elution silica gel vacuum liquid chromatography 
using 20% increment of CHCl3/acetone to furnish eight 
fractions, from which the most inhibitory fraction one was 
again chromatographed in silica gel with 20% gradients 
of  petroleum ether/CHCl3 and CHCl3/acetone to afford five 
fractions.  
  Another portion of UrC (150 g) was subjected to lead (II) 
acetate treatment[17], to give a brown syrup (UrCLa, 15 g)
which was fractionated in silica gel column with 10% 
gradients of CHCl3/acetone to give eight fractions.
2.3. Isolation of compounds 1-7 
  Further purification and identification of 1-7 from these 
fractions are reported elsewhere[8,9]. 
2.4. Microplate alamar blue assay (MABA)[18]
  Briefly, the test compound MICs against TB were assessed 
by the MABA using INH, Moxifloxacin and PA824 as 
positive controls. Compound stock solutions were prepared 
in DMSO at a concentration of 12.8 mM, and the final test 
concentrations ranged from 128 mM to 0.5 mM. 2-fold 
dilutions of compounds were prepared in Middlebrook 7H12 
medium (7H9 broth containing 0.1% w/v casitone, 5.6 mg/mL
palmitic acid, 5 mg/mL bovine serum albumin, 4 mg/mL 
catalase, filter-sterilized) in a volume of 100 mL in 96-well 
microplates (black viewplates). M. tuberculosi H37RV (100 
mL inoculum of 2 to 105 cfu/mL) was added, yielding a final 
testing volume of 200 mL. The plates were incubated at 37 曟.
On the 7th day of incubation 12.5 mL of 20% Tween 80 and 
20 mL of Alamar Blue (Trek Diagnostic, Westlake, OH) were 
added to the test plate. After incubation at 37 曟 for 16 to 24 h,
fluorescence of the wells was measured (ex 530, 590 nm). 
The MICs are defined as the lowest concentration effecting 
a reduction in fluorescence of >90% relative to the mean of 
replicate bacteria only controls.
2.5. Cytotoxicity assay
  Vero cells (ATCC CRL-1586) were cultured in 10% fetal 
bovine serum (FBS) in minimum essential medium Eagle. 
J774A.1 cells were cultured in 10% FBS in Dulbecco’s 
modified Eagle’smedium(DMEM). The cells were incubated 
at 37 曟 under 5% CO2 until confluent and then diluted 
with phosphate-buffered saline to 106 cells/mL. In a 
transparent 96-well plate (Falcon Microtest 96), threefold 
serial dilutions of the macrolide stock solutions resulted in 
final concentrations of 102.4 to 0.42 mM in a final volume 
of 200 mL. After incubation at 37 曟 for 72 h, medium 
was removed and monolayers were washed twice with 100 
mL of warm Hanks’ balanced salt solution (HBSS). One 
hundred microliters of warm medium and 20 mL of freshly 
made MTS-PMS[3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2-tetrazolium 
and phenylmethasulfazone] (100:20) (Promega) were added 
to each well, plates were incubated for 3 h, and absorbance 
was determined at 490 nm.
3. Results
  Results of antitubercular activity of the U. rufa extracts and 
fractions based on data provided by the Microplate Alamar 
Blue assay (MABA)[18] are shown in Table 1. Generally, 
the results showed that antimycobacterial activities of the 
chloroform extract (UrC) and its sub-extracts (UrCP and 
UrCC: P = petroleum ether solubles; C = chloroform solubles) 
and the fractions increased with increasing concentration 
and by further separation and purification. The chloroform 
sub-extract (UrCC) was observed to be the most inhibitory 
extract (MIC = 128 毺g/mL). Chromatographic separation 
of the constituents by increasing solvent polarity in silica 
column afforded fractions namely, UrCC1, UrCC2 and UrCC4 
with enhanced inhibitory rates. Further purification of 
fraction UrCC1 afforded UrCC12 with an MIC of 24 毺g/mL. 
Thin-layer chromatographic phytochemical analysis of the 
latter fraction revealed the presence of steroids, terpenoids 
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and flavonoidal constituents. The fraction was found to have 
an IC50 greater than 102.4 毺g/mL against VERO cells. 
  The known cyclohexenoids 1-5 were isolated from fraction 
UrCC12, UrCC13 and UrCC14[7,8]. With MICs greater than
128 毺g/mL, all compounds were considered inactive.
  The UrC extract treated with lead (II) acetate (UrCLa) was also 
subjected to the MABA assay. Interestingly, extract UrCLa 
(MIC = 24 毺g/mL) and its chromatography were observed 
to have significantly higher inhibitory activity against
M. tuberculosis H37Rv compared to its parent UrC extract. The 
fractions obtained after silica gel fractionation possessed 
lower MIC values ranging from 8-29 毺g/mL against the test 
organism. Likewise, the major compounds 6 and 7 previously 
isolated and purified from fraction UrCLa3 (MIC = 8 毺g/mL)
did not show significant activity against M. tuberculosi H37Rv 
(MIC = >128 毺g/mL).
Table 1




MIC (毺g/mL)128 毺g/mL 64 毺g/mL
UrC 46 18 >128
UrCP 85 70 >128
UrCC 94 70   128
UrCC fractions
              UrCC1 95 72   128
              UrCC2 90 49   128
              UrCC3 71 47 >128
              UrCC4 99 43   128
              UrCC5 53 50 >128
              UrCC6 61 55 >128
              UrCC7 69 56 >128
              UrCC8 74 73 >128
UrCC1 fractions
UrCC11 73 52 >128
UrCC12 99 93     24
UrCC13 99 71   128
UrCC14 91 66   128
UrCC15 87 67 >128
Table 2 
%Inhibition and MIC of the lead acetate-treated chloroform extract 
and its fractions vs. M. tuberculosis H37Rv.
Extract/Fractions
Test concentrations
MIC (毺g/mL)128 毺g/mL 64 毺g/mL
UrCLa 100 100     24
UrCLa1 100   99     13
UrCLa2 100 100     11
UrCLa3   98 100      8
UrCLa4   99 100     14
UrCLa5   99   99     29
UrCLa6   87   37 >128
UrCLa7   99   74   128
UrCLa8   94   74   128
Standard drug: Rifampin (98% @ 0.128 毺g/mL).
Figure 1. Aromatic constituents from U. rufa.
4. Discussion
  Ethnomedically, hundreds of plants worldwide are used in 
traditional medicine as treatments for bacterial infections. 
Some of these have also been directed to in vitro bioassay 
screening but the effectiveness of such herbal medicines 
has seldom been severely tested in controlled clinical trials. 
Conventional drugs usually provide efficient antibiotic 
therapy for bacterial infections but there is an escalating 
problem of antibiotic resistance and a continuing need for 
new medical strategies. Although natural products are not 
necessarily safer than synthetic antibiotics, most patients 
prefer to use herbal medicines. 
  Although much has been reported on the phytochemistry 
of U. rufa, yielding flavonoids and oxidized aromatic 
constituents as the title compounds, little is known about 
the pharmacologic promise of its phytometabolites. The 
ethyl acetate extract of the leaves of U. rufa and its flavonol 
glycoside constituents were previously observed to possess 
advanced glycation end-products (AGEs) inhibitory activity[10]. 
The antimycobacterial activity against M. tuberculosis
H37Rv is a new addition to the activities reported for this 
plant. Conventional extraction makes use of water as 
solvent but in our study and experience, it was indisputably 
established that extraction with organic solvents was 
more efficient in solubilizing potent antituberculosis 
compounds[11-16]. Noteworthy, various extracts and fractions 
obtained by chloroform extraction of the air-dried leaves 
including a lead-acetate treated extract, exhibited potent 
antiproliferative property against M. tuberculosi H37Rv. 
The latter chemical treatment was performed to eliminate 
chlorophyll and other polar pigments[17]. Most phytochemical 
investigations pertaining to anti-TB assay guided isolations 
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have yielded (mostly) compounds of weak to strong polarity 
i.e. steroids, terpenoids, flavonoids, alkylated aromatics 
and lactones, acetylenics and alkaloids among others[4,5]. 
Although no considerable antitubercular activity was 
observed for the compounds known for this plant (1-7)
[7,8], it is worth noting that many other constituents may 
be isolated from the antitubercular fraction UrCC12 
which was also observed to be non-cytotoxic to VERO 
cells. The toxicity assessment against VERO cells may 
model toxicity to mammalian cells. Thus, with potent 
antimycobacterial activity, fraction UrCC12, the cytotoxicity 
test result indicate that it maybe a good source of anti-
TB compounds with selective activity. In addition, thin-
ayer chromatographic analysis indicated the presence of 
phytochemical constituents such as flavonoids that may 
demonstrate a promising antitubercular activity. It has been 
reported that flavonoids exhibit antimycobacterial activity 
by inhibiting enzymes involved in the fatty acid and mycolic 
acid biosynthesis[19]. Furthermore, several flavonoids were 
also observed to have isoniazid (INH) modulating activities 
and thus could be administered with anti-TB treatment to 
prevent or counter resistance to INH[20]. Therefore, further 
investigations warrant the isolation of bioactive principles 
which may become future alternative therapeutic agents for 
tuberculosis.
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